BioSpace News Archive

Health Catalyst, Inc. will release its first quarter 2024 operating results on Thursday, May 9, 2024, after market close.

scPharmaceuticals Inc. today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

SensaSure Technologies and Verde Bio Holdings Provide Update on Pending Merger.

Pasithea Therapeutics Corp. today announced the first cohort of 3 patients have commenced dosing. PAS-004 is being evaluated in a Phase 1 multicenter open label clinical trial (NCT06299839 ) in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition.

GV20 Therapeutics today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.

Lykos Therapeutics announced the completion of a European Phase 2 study (MP18), an open-label, multicenter feasibility study of investigational midomafetamine (MDMA) capsules used in combination with psychological intervention (“MDMA-assisted therapy”) for adults with post-traumatic stress disorder (“PTSD”).

Chiesi Global Rare Diseases today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.

Lantern Pharma Launches “ Webinar Wednesdays ” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development.

Strategic collaboration to leverage BigHat’s AI/ML (Artificial Intelligence / Machine Learning) guided Milliner™ platform to design high-quality next-generation protein therapeutics.

Kiromic BioPharma, Inc. announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™.